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Background: If you want to know which of two or more healthcare interventions is most effective, the randomised
controlled trial is the design of choice. Randomisation, however, does not itself promote the applicability of the
results to situations other than the one in which the trial was done. A tool published in 2009, PRECIS (PRagmatic
Explanatory Continuum Indicator Summaries) aimed to help trialists design trials that produced results matched to
the aim of the trial, be that supporting clinical decision-making, or increasing knowledge of how an intervention
works. Though generally positive, groups evaluating the tool have also found weaknesses, mainly that its inter-rater
reliability is not clear, that it needs a scoring system and that some new domains might be needed. The aim of the
study is to: Produce an improved and validated version of the PRECIS tool. Use this tool to compare the internal
validity of, and effect estimates from, a set of explanatory and pragmatic trials matched by intervention.
Methods: The study has four phases. Phase 1 involves brainstorming and a two-round Delphi survey of authors
who cited PRECIS. In Phase 2, the Delphi results will then be discussed and alternative versions of PRECIS-2
developed and user-tested by experienced trialists. Phase 3 will evaluate the validity and reliability of the most
promising PRECIS-2 candidate using a sample of 15 to 20 trials rated by 15 international trialists. We will assess
inter-rater reliability, and raters’ subjective global ratings of pragmatism compared to PRECIS-2 to assess convergent
and face validity. Phase 4, to determine if pragmatic trials sacrifice internal validity in order to achieve applicability,
will compare the internal validity and effect estimates of matched explanatory and pragmatic trials of the same
intervention, condition and participants. Effect sizes for the trials will then be compared in a meta-regression. The
Cochrane Risk of Bias scores will be compared with the PRECIS-2 scores of pragmatism.
Discussion: We have concrete suggestions for improving PRECIS and a growing list of enthusiastic individuals
interested in contributing to this work. By early 2014 we expect to have a validated PRECIS-2.
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Pragmatic trial design hit the research headlines in
September 2011 over the discussion of the Advisory
Committee to the US Food and Drug Administration
(FDA) to approve rivaroxaban to minimise stroke risk
for patients with atrial fibrillation [1]. This decision to
recommend rivaroxaban, over the more well-known alter-
native anticoagulant treatment warfarin, was not unani-
mous; debate arose over the pragmatic study design used* Correspondence: K.Loudon@dundee.ac.uk
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reproduction in any medium, provided the orin the trial and the applicability of the trial results. The
majority (9 vs. 2, one abstention) thought the pragmatic
design of the ROCKET AF trial was good but some
questioned the rigor of the design and the compliance
rates seen in the trial. The debate highlighted the impact
design decisions have on clinicians’ and others’ confidence
in trial results and, in particular, the need to select patients
who are ‘truly reflective of the type of patients physi-
cians would see in everyday practice’ [1].
In the UK, the National Institute for Health and Cli-
nical Excellence (NICE) is often embroiled in debate
over decisions for recommending or withholding treat-
ments if uncertainties over a treatment’s effects. If NICEl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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not proven to have an effect should only be administered
to patients in the NHS through research,) following
Health Technology Appraisals, this is often taken as a ‘No’
to a new treatment [2]. Hence the role of pragmatic
randomised controlled trials (RCTs) in comparative effect-
iveness research is of increasing interest in producing evi-
dence for ‘real world’ benefits and risks [3].
Pragmatic trials were first proposed by Schwartz and
Lellouch in 1967 as trials performed under normal con-
ditions with the intention of providing results that are more
applicable to clinical practice and decision-making. The al-
ternative, taking a more explanatory approach, leads to
tightly controlled trials under ideal conditions that aim to
provide understanding of how treatments work [4]. Ex-
planatory trials have an important role but healthcare in-
terventions are seldom given under circumstances similar
to those used in such trials [5,6]. Many authors have
highlighted the need for trials with greater applicability
[7-9]; in other words, trials that pay attention to external
validity as well as internal validity. Lack of consideration
of external validity is the most frequent criticism by clini-
cians of RCTs, systematic reviews and guidelines [7].
But how does a trialist know that his or her trial has
the right design? In 2009 a tool called the Pragmatic
Explanatory Continuum Index Summary (PRECIS) was
published simultaneously in two journals to help trialists
think more carefully about the impact their design deci-
sions would have on applicability [10,11]. PRECIS is aFigure 1 Pragmatic Explanatory Continuum Indicator Summary (PREC10-spoked ‘wheel’ (see Figure 1 and Additional file 1)
with 10 domains based on trial design decisions (for ex-
ample, participant eligibility criteria, practitioner expertise
and choice of comparator). Trials that take an explanatory
approach produce wheels nearer the hub; those with a
pragmatic approach are closer to the rim.
Our hypothesis is that pragmatic trials do not com-
promise internal validity (we should not mistake real-
ism for bias) and that explanatory trials overestimate
effect size compared to more pragmatic designs and
that recommendations regarding trial design, espe-
cially for regulatory trials, need to be modified. A
modified PRECIS tool is, however, needed first to be
able to separate explanatory and pragmatic trials in a
consistent way.Prior research rationale
PRECIS was developed by more than 25 international
trialists and methodologists, including ST and MZ, work-
ing between 2005 and 2008 [12], linked to simultaneous
work on the CONSORT extension for pragmatic trials
[13]. The aim was to produce a tool that helped trialists
match their design decisions to the purpose of the trial, be
that informing a clinical decision or increasing knowledge
of how an intervention works. Currently, PRECIS provides
a simple graphical summary of 10 key design decisions
(see Figure 1) to assist trial designers in ensuring their
decisions are consistent with the purpose of the trial.IS) [10].
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group of methodologists and trialists have used the tool;
it is interesting to note who has used the PRECIS, as it
was developed for all trialists to make design decisions
[10]. Eight groups have studied PRECIS [14-21] and
these studies have all concluded that PRECIS was useful
in designing trials, or to assess how pragmatic or explana-
tory trials included in systematic reviews were. All sug-
gested that PRECIS needed some modifications.
PRECIS studies
In the study by Riddle [14] planning total knee surgery
the trial investigators came from a wide range of special-
ties (physical therapy, biostatistics, rehabilitation medi-
cine, psychiatric and behavioural sciences, medicine,
rheumatology). Riddle [14] found the PRECIS tool useful
for discussing trial design and achieving consensus dur-
ing a 1-day face-to-face meeting. To enable constructive
discussion Riddle [14] used a PRECIS wheel with spokes
that were 0 to 4 cm in length with the zero point at the
hub (explanatory) and 4 cm at the rim of the wheel
(pragmatic). They used the tool as it was intended - to
design the protocol for a clinical trial; pre-meeting, ideal
score and post-consensus meetings when all the raters
were present but blinded to each other’s score. Raters
marked a point on the wheel which was then measured.
This must have been a little time-consuming but allowed
the participants to quantify disagreement between raters
which could then be discussed. Variation in scoring for
the 10 PRECIS categories, as reflected in average stand-
ard deviation moved from initial assessment of 0.83, to
1.16 for the ideal trial for individual raters, to 0.61 for
the final assessment.
In his first paper using PRECIS, Bratton [18] scored
three trials on tuberculosis treatment with another re-
searcher. They combined the spokes on expertise and
inserted a domain for ‘blinding’ and found the tool help-
ful to pinpoint weaknesses in the trial design as well as
assisting trialists to consider the applicability of their tri-
als. Bratton [21] then used PRECIS again in an ongoing
trial of an autoimmune disease non-inferiority trial; the
degree of pragmatism was considered by a trial manager,
two clinicians with expertise in the trial area of pem-
phigoid and two statisticians. Bratton [21] advocated the
procedure described by Riddle [14] and so his group also
used a blank PRECIS wheel approximately 15 cm in
diameter. While they recommended using PRECIS to
achieve consensus they had a few concerns that there
was a great deal of variability scoring domains depend-
ing on expertise of raters and interpretation of guidance
from the original Thorpe paper [10,11].
In the study by Tosh et al. [15], three doctors who had
research backgrounds and specialised in psychiatry, used
PRECIS to evaluate mental health protocols. Tosh’s [15]group decided they wanted to quantify how pragmatic
10 protocols were, and decided to score PRECIS using 1
(most explanatory) to 5 (most pragmatic) with zero for
domains that did not contain any information. They
used 0 to 30 for an explanatory trial, 31 to 39 for a trial
balanced between pragmatic and explanatory, and 40 to
50 for a pragmatic trial. Calling their modified PRECIS,
the Pragmascope tool, reliability was reasonable for the
raters (weighted Kappa = 0.72).
Koppenaal et al. [17] adapted PRECIS - PRECIS-
Review tool (PR-tool) - to rate trials in a systematic re-
view to determine which intervention would improve
lifestyle most in general practice. As the original PRECIS
tool produces a wheel like figure for each trial with no
scoring system, it is hard to assess how applicable to
routine care a systematic review is. So, Koppenaal et al.
[17] proposed scoring the domains and each trial using a
scoring system of 1 to 5 as well as 0 to 100%; they found
that a scale of 1 to 5 was less subjective compared with
a 0 to 10 scale. By scoring all the trials in the systematic
review they were able to determine which trial was most
pragmatic and overall how pragmatic and thus how ap-
plicable the review was. They were also able to deter-
mine how heterogeneous the individual trials were. They
did have concerns though about arbitrary scoring and
that more pragmatic scoring occurred when there was
inadequate information. Koppenaal et al. [17] proposed
that two researchers should score RCTs to improve val-
idity. His team also highlighted problems with context
that the PR-tool did not pick up and that weighting of do-
mains may be dependent on the situation. Overall he con-
cluded that the PR-tool-PRECIS with a scoring system
was very helpful to users of RCTs and systematic reviews.
Glasgow et al. [16] invited nine raters who were med-
ical doctors or had doctorates and were experienced
researchers to use PRECIS; six were involved in the tri-
als they were rating, Practice-based Opportunities for
Weight Reduction (POWER) and three independent
raters who had nothing to do with the trials being
scored. Glasgow et al. [16] used a score from 0 (most
pragmatic) to 4 (most explanatory) but the researchers
required several conference calls to discuss the domains
and scoring. There were problems with inter-rater reli-
ability and raters determining that their own trial was
more pragmatic than independent raters; Glasgow
questioned if this was due to bias or more trial
knowledge.
Witt et al. [19] used PRECIS to evaluate acupuncture
trials for a systematic review. Her team of PhD and MD
raters had more than 10 years of experience in clinical
research and had worked on aspects of research meth-
odology, with experience in acupuncture. Witt et al. [19]
also chose to use a score, 1 to 5, to allow score compari-
sons of inter-rater correlations and ensuring results could
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observed that the first round of scorings were highly
heterogeneous but that inter-rater reliability improved
following discussion of domains.
Selby et al. [20] for a trial on smoking cessation
had a team of six raters with a range of expertise
(one academic family physician with an interest in
smoking cessation; one cardiac rehabilitation phy-
sician with expertise in pharmacoeconomics; one ad-
diction medicine physician and clinical scientist with
a focus on tobacco dependence; one pharmacist with
expertise in pharmacoeconomics; one pharmacologist
with clinical research and medical affairs experience
in the pharmaceutical industry; and one consultant
physician with pharmacoeconomics and policy advice
experience in Quebec). Selby et al. [20] highlighted
how difficult it was to use a Visual Analogue Scale
for raters working online using PRECIS to guide the
protocol development of a smoking cessation trial. As
the printers they were using were all different, so too hard
to use a VAS for comparison purposes, they chose to use a
20-point scale, where 1 represented ‘entirely explanatory’
and 20 represented ‘entirely pragmatic’ making it easier to
score using email. They scored the protocol twice using a
modified Delphi process. Selby advocates that using a sys-
tem of scoring PRECIS anonymously allows different
views to be expressed and assists in consensus decision-
making from multidisciplinary raters. This ensures the
best design to answer the study question. Rater scores var-
ied less after the second round than the first indicating
convergence in opinions following discussion.
To summarise, all published users of PRECIS have
used either Visual Analogue Scales or Likert scoring
systems to enable individual raters to compare decisions
and measure how pragmatic or explanatory a domain is.
Most groups have also used PRECIS for consensus
decision-making. A summary of their key findings is in
Table 1.
Study objectives
1. To produce an improved and validated version of
the PRECIS tool.
2. To use this tool to compare the internal validity of,
and estimate effect from, a set of explanatory and
pragmatic trials matched by intervention.
Methods
Study design
There will be four phases to the study.
 Phase 1: We will develop PRECIS-2 through expert
consensus and conduct a two-round electronic
modified Delphi survey. Phase 2: Alternative PRECIS-2 models will be user-
tested in Dundee, Scotland and London, Ontario,
Canada using one-to-one testing or small group
testing.
 Phase 3: Validity and reliability testing of PRECIS-2
using a sample of 15 to 20 trials and a minimum of
15 trialists/methodologists from around the world.
 Phase 4: Comparing the internal validity and effect
estimates of matched explanatory and pragmatic
trials
General and phase 1
First, we will establish a steering group (PD, KL, ST, FS,
MZ). Second, we will design the first round of a modified
Delphi consensus method [22] to discuss improving the
current PRECIS tool and create PRECIS-2. We will gener-
ate a web-based questionnaire using the SurveyMonkeyW
survey tool ‘select’ version (that is, not the free version).
It is widely accepted that the initial round of a modified
Delphi process can be a structured questionnaire if there
has been a systematic review of the literature and there
is adequate information to base the survey on [23,24].
Our questionnaire will be based on problems that have
been published by users of PRECIS and the report from
a brainstorming meeting at the University of Dundee on
8 June 2012. Topics to be discussed in the survey will
include Scoring, Domains and Design. There will be an
introduction to the survey and all participants will be
advised that their assistance in participation in the
survey will be acknowledged in any future publication.
We will be careful in designing the questionnaire not to
lead respondents into expected answers but keep questions
open to gain maximum information, allowing us to develop
a full range of PRECIS alternative models for user testing
and ‘explore or expose underlying assumptions’ [25].
The survey will take around 10 minutes. It will not
be compulsory for participants to answer any of the
questions. All participants will have an opportunity to
leave comments as well as multiple choice yes or no
answers. Responses from individuals will be known
only to the moderator (KL), so participant anonymity
and confidentiality of responses will be ensured. Rea-
sons for declining participation will be collated if
solicited.
We will pilot test the SurveyMonkeyW questionnaire
with the PRECIS steering group and the four partici-
pants involved in the initial Dundee brainstorming
meeting (June 2012) until the steering group are satis-
fied with the Survey. We will invite (by email using
MailMerge) all those who have cited PRECIS from the
Thorpe 2009 [10,11] publications and have not previ-
ously been involved in the development of PRECIS
to participate in in all four phases and start by comple-
ting SurveyMonkeyW questionnaire to give advice to
Table 1 Summary of existing work with PRECIS
Reference Scale RCTs Protocols Raters
(n)
Consensus
scoring
Comments
Riddle (2010) Pain coping skills
training for patients - knee
arthroscopy
0-4 cm
circle
VAS
X 1 7 YES (individual
scoring then
consensus score)
Useful to focus trial design discussion. PRECIS scoring:
Initial, personal ideal and then post meeting. 1-day
face-to-face meeting to discuss trial. PRECIS facilitates
discussion.
Trial design changed: domain ‘practitioner expertise’ -
needed to do psychologist training and domain
‘practitioner adherence’ - rigorous ongoing assessment
to check intervention as intended. Visual analogue scale
cannot be used if ‘online ratings’.
Glasgow (2010) Weight loss in
obese patients with comorbid
conditions
0-4
scale
3 X 9 NO PRECIS improved ‘transparency’ in trial design decisions,
encouraged others to use.
Domain most variation: Primary analysis.
Trialists rate own trial more pragmatic than other raters.
Not clear if original criteria are sufficient to provide a
comprehensive profile.
Tosh (2011) Mental health 1-5 X 10 3 NO ‘Useful tool’. Cumulative scores for all 10 PRECIS
domains. Experimental 0–15, Pragmatic >35, 31–19
interim where trial balances pragmatic and explanatory
domains. Scoring depends on rater’s perspective. 0 for
missing information
Koppenhaal (2011) Systematic
review on lifestyle
improvements in General
Practice
1-5% 20 X 2 YES (individual
scoring then
consensus score)
‘Useful estimate by estimating quantitatively how
pragmatic each RCT is’. Chose PRECIS as explanatory/
pragmatic continuum and visual analogue scale. Domains
most variation: Practitioner expertise (comparison), primary
analysis. Tried 1–10 score but too much difference
between consecutive scores not meaningful, still
concerned arbitrary - important to reduce subjectivity so
two raters (third rater if not consensus). Weighting could
be important; eligibility criteria important but flexibility of
the comparison intervention may be less important.
Problems using PRECIS due to reporting as CONSORT
guidelines not being followed.
Bratton (2011) No
scoring
3 X 2 Joint discussion Blinding inserted and combined experience of
practitioner expertise for comparison and experimental
intervention as postulated no difference in expertise in
these trials.
Bratton (2012) 1
(ongoing)
X 6 NO ‘Useful tool for designing, conducting and reporting
trials’. Strongest consensus ‘flexibility of the comparison
intervention’ and ‘practitioner adherence’ domains.
Most disagreement on ‘eligibility criteria’ and
‘participant compliance’.
Witt (2012) 1-5 10 X 5 YES (individual
scoring then
consensus score)
“PRECIS useful but needs further development”.
CONSORT guidelines for reporting pragmatic trials
should be expanded. Recognised that PRECIS originally
intended for trial design but useful tool for appraising
published RCTs for systematic reviews.
Selby (2012) 1-20 X 1 6 YES (individual
scoring then
consensus score)
PRECIS useful to help interdisciplinary co-investigators
rate their study design. Used two rounds of Modified
Delphi process used to reach consensus. 20-point
numerical scale approximated a continuous scale
allowing ‘easier, more accurate and more stable coding
of the response using e-mail’ - extreme anchor points
1–20, discouraged rating the domains beyond the
numbers provided.
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ested colleagues or let us know if they know of anybody
who may be interested in participating.
We will send out reminders after 2 weeks, and another
reminder to those who had initially said they wereinterested but who had not completed the survey after a
further 2 weeks to optimise recruitment [26]. We will
take note of the response rate for the first round, pre
and post reminder before moving onto the second
round. Following the first round of the Delphi, the
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topics to go forward to the next round. A report will be
prepared for all participants based on Round 1 responses
and a link for a further Delphi round using SurveyMonkeyW
will be sent to everyone who has stated their interest (pilot
tested as described before). A further reminder will be sent
for the Delphi Round 2 participants to encourage ma-
ximum participation and response rates will be noted. A
report will be prepared for all Round 2 participants.
Through brainstorming, the Steering group will use the
results of the second round of the Delphi, including
free-text responses, to develop PRECIS-2 models. Ad-
ditional input may be sought from the Dundee brain-
storming group in finalising models for Phase 2 user
testing.
Phase 2
A review of the first part of Phase 1 will be given as an
introduction at meetings in Dundee, Scotland and
London, Canada which will be attended by participants
gathered for user testing of different PRECIS models.
This will be on a one-to-one basis or in small groups.
User-testing [27] involves, a user (for example, a trialist)
being presented with the tool being tested (for example,
PRECIS-2) and a topic list of questions and tasks involv-
ing a specific trial that makes use of the tool. The key ad-
vantages of user-testing are that it provides feedback from
the user’s perspective and is quick; testing generally takes
no more than 1 hour. We will also use a brief training
package at the start of the meeting. To encourage max-
imum participation from all participants, the user testing
group size will be small. Ideally this will be six people
maximum but logistically this may not always be possible.
Discussion on the different PRECIS models will be facili-
tated by KL, assisted by MZ or ST. One-to-one user test-
ing will be carried out by KL or ST with the other acting
as the assistant. With permission of participants, all meet-
ings will be audio-taped and then transcribed. If the
participant does not give permission then only notes will
be taken during user testing of PRECIS models.
Models for user testing will pick up on themes
highlighted in Phase 1, in particular scoring (if at all),
weighting, domains and design. We will make sure that
we include head-to-head comparisons between the old
and the new PRECIS tools. The topic guide with questions
for the user will be piloted by the Dundee Brainstorming
participants and the Steering group prior to Phase 2 user
testing commences.
The project team will review notes and transcriptions
together after each test, looking for barriers and facilita-
tors to the use of PRECIS-2, categorised according to the
severity of the problem: high (critical errors such as incor-
rect interpretation or high degree of uncertainty or dissa-
tisfaction), medium (much frustration or unnecessarilyslow use), and low (minor or cosmetic problems). By
modifying PRECIS-2 in response to user-testing, and then
testing the new version in further user-testing, the tool will
be much more likely to be relevant and useful to its
intended user group of trialists and methodologists. The
version of PRECIS-2 that finally emerges from iterative
user-testing will be put into Phase 3.
Phase 3: validity and reliability testing
Unlike with the development of the original PRECIS, we
intend to formally test PRECIS-2’s validity and reliability
at the development stage. To be feasible, and to ensure
that a diverse range of trialists and methodologists can be
involved, we will use an electronic process for this work.
The electronic process will involve a minimum of 15
trialists/methodologists from around the world consider-
ing a mixed sample of trial reports (chosen by the Steering
Group during Phase 1 and 2) using PRECIS-2. All partici-
pants will be sent a concise PRECIS-2 training package
and between 10 and 15 trials (See Sample size and statis-
tics). Some will be extremely pragmatic in design, some
extremely explanatory, with the other trials a mixture.
These trials will be selected to exemplify the different trial
types and demonstrate particular aspects of trials that
would stimulate discussion to develop PRECIS-2. Some
will be drug trials. Participants will be asked to give sub-
jective global ratings of pragmatism before being asked to
use PRECIS-2. If necessary we will modify PRECIS-2 and
repeat the exercise with trialists and methodologists if val-
idity and reliability are initially poor. Rating a trial using
PRECIS takes between 10 and 20 minutes and we expect
PRECIS-2 to be similar. There will be a financial payment
to each trialist/methodologist completing the PRECIS-2
ratings of approximately £200.
Phase 4: Comparing the internal validity and effect
estimates of explanatory and pragmatic trials
By the end of Phase 3 we will have a validated tool
(PRECIS-2) for judging how explanatory or pragmatic
a clinical trial is. Phase 4 will use this tool to answer
speculation [28,29] that pragmatic trials sacrifice in-
ternal validity in order to achieve applicability.
We will use the PRECIS-2 tool to create a database of
around 200 trials that take a pragmatic approach to de-
sign, are rated for pragmatism (using PRECIS-2) and risk
of bias and which collate information on effect size. We
have developed and tested an initial search strategy for
this search:
1. ‘pragmatic trials’
2. ‘management trials’
3. ‘efficiency trials’
4. ‘practical trials’
5. ‘effectiveness trials’
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7. ‘field trials’
8. ((‘real-world’ OR ‘real life’) AND trials OR trial))
9. MH ‘Clinical Trials as Publication Type’
10. S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8
11. S9 AND S10
This search is being refined at the time of writing and
will be in a definitive state by the start of Phase 4. We
will extract the following information from all retrieved
trials: topic of trial, number of centres, sample size,
randomization, allocation and blinding methods, type of
statistical analyses, participant characteristics (for ex-
ample, age, condition, baseline severity and so on), dur-
ation of trial, and effect sizes and measures of variance
for the primary outcome. The degree of pragmatism will
be assessed using the PRECIS-2 tool and the risk of bias
assessed using the Cochrane Risk of Bias Tool [30]. The
database will be made publicly available as a searchable
and extendable (that is, new studies can be added) web
resource. In addition to the database, we will make
PRECIS-2 training and other guidance, a summary of
other PRECIS literature and other tools to support the
design of trials available via the website.
Next we will match some of the pragmatic trials
with more explanatory trials of the same intervention,
condition and participants. It is impossible to say
which interventions we will match without having
created the database of pragmatic trials but it is al-
most certain that all the interventions we will use for
matching will be drugs. We will extract the same in-
formation for these matched trials as we extracted for
the more pragmatic trials. Effect sizes for the trials
will then be compared in a meta-regression (see Sam-
ple size and statistics).
Participants
We will involve an international group of methodolo-
gists and trialists, healthcare professionals, and other in-
dividuals with trial expertise, in particular researchers
who have stated an interest in the project and said that
they would like to be involved in the validation of
PRECIS-2. This will include those involved in the
original PRECIS tool development.
Identifying participants
We will initially identify participants to assist in PRECIS
development, starting with the SurveyMonkeyW ques-
tionnaire, from all those who cited the original Thorpe
et al. articles [10,11] via email invitation. Participants in
additional phases will be those who stated they wanted
to take part in the Delphi survey, and trialists and meth-
odologists known to the PRECIS steering group through
collaborations including the Cochrane MethodologyReview Group, the CONSORT Group, the Scottish Clin-
ical Trials units and the EC FP7 DECIDE project. We
also have a list of researchers who have worked with
PRECIS, some of whom have contacted us directly re-
garding collaboration.
Informed consent
Consent will be implied by the participants if they agree
to participate by returning completed questionnaires in
the different phases. With participants’ permission, the
Phase 2 discussion in the one-to-one or group testing
will be audio recorded and then transcribed. If a partici-
pant would rather that the discussion is not recorded,
we will not record the discussion and take only written
notes during the discussion. Audio recordings will be
stored digitally as encrypted files on University servers,
protected by standard University firewall and back-up
processes. Data will be kept for no longer than 5 years.
Duration
The project started on 1 October 2012 and will run for
16 months. This work forms part of KL’s PhD work
which finishes 30 September 2014.
Ethics
The study was approved by the University of Dundee
Ethics Committee, UREC 12107.
Sample size and statistics
We will measure PRECIS-2’s inter-rater reliability using
the intraclass correlation coefficient (ICC). The sample
size depends on the number of raters and the number of
trials these raters assess. As stated earlier, rating a trial
using PRECIS takes between 10 and 20 minutes and we
expect PRECIS-2 to be similar so the sample size is a
compromise between precision and what we can reason-
ably ask raters to do. If we assume the ICC will be in the
region of 0.7 (considered strong agreement) then 15
raters looking at 10, 15 or 20 trials would give precisions
of 0.20, 0.17 and 0.14, respectively. We will aim to give
our 15 raters between 10 and 15 trials to rate, depending
on what Phase 1 tells us about the acceptable workload
for raters; we will go beyond 15 if PRECIS-2 is quicker
to complete than PRECIS.
For Phase 3 we will assess inter-rater reliability, and
raters’ subjective global ratings of pragmatism compared
to PRECIS-2 to assess convergent and face validity. We
will determine if PRECIS-2 can accurately discriminate
trials of varying pragmatism as judged by the subjective
rating by calculating odds (discriminant validity).
Phase 4 will involve matched (by intervention) pairing
of pragmatic and explanatory trials. All effect sizes will be
converted to relative effect measures (for example, odds
ratios or log odds) or difference measures (for example,
Loudon et al. Trials 2013, 14:115 Page 8 of 9
http://www.trialsjournal.com/content/14/1/115mean difference). We will then perform a random effects
meta-analysis across all trials and apply meta-regression
analyses with type of trial (explanatory and pragmatic
trials; binary coded) as an independent variable and
overall effect as the dependent variable. The Cochrane
Risk of Bias scores will be compared for the matched ex-
planatory and pragmatic trials to assess internal validity,
in particular: sequence generation, allocation sequence
concealment; blinding of participants, personnel and
outcome assessors; incomplete outcome data; selective
outcome reporting; other potential threats to validity
like publication bias. We will test the hypothesis that
pragmatic trials have a greater risk of bias than trials
that take a more explanatory approach.
We will also perform multivariate regression in to at-
tempt to further explain variation in effect (for example,
are topic of trial, risk of bias, sample size, degree of prag-
matism and so on predictive of intervention effect size).
We will apply backward step-wise regression to arrive at
only significant covariates (P <0.05) and obtain P values.
Goodness-of-fit for models will be assessed using Akaik’e
Information Criterion (AIC), where lower values are bet-
ter. If there are less than 10 trials per covariate, we will
also apply permutation-based resampling on all significant
covariates and extract resultant P values.
Statisticians from the Dundee Epidemiology and Bio-
statistics Unit will support all these analyses.
Discussions
Healthcare systems and guideline producers need trials to
provide data that are relevant to the clinical decisions
made by patients, health professionals and policy-makers.
Many trials, however, are less applicable than they could
be because participants are highly selected (for example,
people in an osteoporosis trial may be selected so that they
have no co-morbidities even though many patients with
osteoporosis do have them), outcomes that are not so im-
portant (for example, measuring bone density rather than
fractures), only expert clinicians are included, or because
of some other departure from usual practice conditions.
These result in a great deal of resources being put into tri-
als that are not as useful as they should be.
This study will involve a large number of trialists,
methodologists and others to obtain suggestions for how
the original PRECIS tool can be improved and will then
validate a modified version of this tool, PRECIS-2.
PRECIS-2 will help people designing trials think more
carefully about the impact their decisions will have on
others’ ability to use the results. It will also help trialists
who do not have years of experience designing clinical
trials to design trials. The original PRECIS tool is highly
cited; a better tool is likely to have an even greater
impact on trial design. Moreover, our links with UK
trials units and international groups of trialists andmethodologists mean that the tool can be expected to
impact trial design internationally from an early stage.
The study will also aim to end speculation as to whether
pragmatic trials have a lower internal validity than more
explanatory trials and, in addition, whether explanatory
trials lead to higher estimates of treatment effect. The
results of this project may have significant consequences
for the way trials, especially regulatory trials, are
designed.
Study status
We have started recruiting to the qualitative work but not
to the quantitative part of the study, the validation part.
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